Dr Reddy's Laboratories Long-Term Investments 2012-2026 | RDY
Dr Reddy's Laboratories long-term investments from 2012 to 2026. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
- Dr Reddy's Laboratories long-term investments for the quarter ending March 31, 2026 were $174M, a 2.25% decline year-over-year.
- Dr Reddy's Laboratories long-term investments for 2025 were $0.178B, a 182.54% increase from 2024.
- Dr Reddy's Laboratories long-term investments for 2024 were $0.063B, a 3.08% decline from 2023.
- Dr Reddy's Laboratories long-term investments for 2023 were $0.065B, a 38.1% decline from 2022.
|
Dr Reddy's Laboratories Annual Long-Term Investments (Millions of US $) |
|
|---|---|
| 2025 | $178 |
| 2024 | $63 |
| 2023 | $65 |
| 2022 | $105 |
| 2021 | $114 |
| 2020 | $41 |
| 2019 | $49 |
| 2018 | $71 |
| 2017 | $106 |
| 2016 | $50 |
| 2015 | $62 |
| 2014 | $13 |
| 2013 | $13 |
| 2012 | $7 |
|
Dr Reddy's Laboratories Quarterly Long-Term Investments (Millions of US $) |
|
|---|---|
| 2026-03-31 | $174 |
| 2025-12-31 | $111 |
| 2025-09-30 | $110 |
| 2025-06-30 | $133 |
| 2025-03-31 | $178 |
| 2024-12-31 | $105 |
| 2024-09-30 | $71 |
| 2024-06-30 | $63 |
| 2024-03-31 | $63 |
| 2023-12-31 | $100 |
| 2023-09-30 | $71 |
| 2023-06-30 | $60 |
| 2023-03-31 | $65 |
| 2022-12-31 | $76 |
| 2022-09-30 | $75 |
| 2022-06-30 | $66 |
| 2022-03-31 | $105 |
| 2021-12-31 | $88 |
| 2021-09-30 | $101 |
| 2021-06-30 | $128 |
| 2021-03-31 | $114 |
| 2020-12-31 | $118 |
| 2020-09-30 | $54 |
| 2020-06-30 | $45 |
| 2020-03-31 | $41 |
| 2019-12-31 | $46 |
| 2019-09-30 | $60 |
| 2019-06-30 | $57 |
| 2019-03-31 | $49 |
| 2018-12-31 | $46 |
| 2018-09-30 | $52 |
| 2018-06-30 | $53 |
| 2018-03-31 | $71 |
| 2017-12-31 | $78 |
| 2017-09-30 | $74 |
| 2017-06-30 | $83 |
| 2017-03-31 | $106 |
| 2016-12-31 | $109 |
| 2016-09-30 | $96 |
| 2016-06-30 | $50 |
| 2016-03-31 | $50 |
| 2015-12-31 | $71 |
| 2015-09-30 | $55 |
| 2015-06-30 | $77 |
| 2015-03-31 | $62 |
| 2014-12-31 | $16 |
| 2014-09-30 | $15 |
| 2014-06-30 | $14 |
| 2014-03-31 | $13 |
| 2013-12-31 | $13 |
| 2013-09-30 | $12 |
| 2013-06-30 | $11 |
| 2013-03-31 | $13 |
| 2012-12-31 | $18 |
| 2012-09-30 | $12 |
| 2012-06-30 | $11 |
| 2012-03-31 | $7 |
| 2011-12-31 | $7 |
| 2011-09-30 | $7 |
| 2011-06-30 | $7 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $11.109B | $3.811B |
| Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |